New Feature Coming Soon, Stay Tuned!
Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
NASDAQ
Pre-market NaN$
0.00 (0.00%)
Relative Strenght
Volume Buzz
170%
Earning Acce
No
Dist 52w H.
95%